|
CNCE
|
Concert Pharmaceuticals, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
CGEM
|
Cullinan Management, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
CDXS
|
Codexis, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
CCCC
|
C4 Therapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
BCAB
|
BioAtla, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
AVIR
|
Atea Pharmaceuticals, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ALLK
|
Allakos Inc.
|
0.03%
|
US
|
NASDAQ
|
|
ABUS
|
Arbutus Biopharma Corporation
|
0.03%
|
US
|
NASDAQ
|
|
DYN
|
Dyne Therapeutics, Inc.
|
0.03%
|
US
|
NASDAQ
|
|
VYGR
|
Voyager Therapeutics, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
TARS
|
Tarsus Pharmaceuticals, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
STOK
|
Stoke Therapeutics, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
SEER
|
Seer, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
NKTX
|
Nkarta, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
MRNS
|
Marinus Pharmaceuticals, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
MGTX
|
MeiraGTx Holdings plc
|
0.02%
|
US
|
NASDAQ
|
|
LYEL
|
Lyell Immunopharma, Inc.
|
0.02%
|
US
|
NASDAQ
|
|
LCTX
|
Lineage Cell Therapeutics, Inc.
|
0.02%
|
US
|
AMEX
|
|
KPTI
|
Karyopharm Therapeutics Inc.
|
0.02%
|
US
|
NASDAQ
|